JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)

JPMorgan Chase & Co. boosted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 548.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 33,991 shares of the company’s stock after buying an additional 28,748 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.11% of Acrivon Therapeutics worth $238,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in shares of Acrivon Therapeutics during the second quarter valued at $58,000. Barclays PLC raised its holdings in Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after purchasing an additional 11,273 shares during the last quarter. Exome Asset Management LLC acquired a new position in Acrivon Therapeutics during the 3rd quarter valued at about $817,000. Finally, State Street Corp boosted its stake in shares of Acrivon Therapeutics by 26.4% in the 3rd quarter. State Street Corp now owns 225,896 shares of the company’s stock valued at $1,581,000 after purchasing an additional 47,233 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Trading Up 4.8 %

ACRV stock opened at $6.07 on Friday. Acrivon Therapeutics, Inc. has a 1-year low of $3.19 and a 1-year high of $11.90. The firm has a market cap of $189.00 million, a PE ratio of -2.25 and a beta of 0.77. The business’s 50-day moving average price is $6.34 and its two-hundred day moving average price is $7.34.

Analyst Upgrades and Downgrades

ACRV has been the topic of several analyst reports. KeyCorp began coverage on shares of Acrivon Therapeutics in a report on Friday. They issued an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Cantor Fitzgerald assumed coverage on Acrivon Therapeutics in a research report on Friday. They issued an “overweight” rating on the stock. Finally, BMO Capital Markets dropped their price objective on Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Acrivon Therapeutics presently has an average rating of “Buy” and a consensus price target of $23.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.